Table 2 Comparison of treatment responses and clinical outcomes of patients infected with SARS-CoV-2 between non-severe and severe group
Variable | Total (N = 100) | Non-Severity (n = 51) | Severity (n = 49) | P Value |
|---|---|---|---|---|
Treatments n (%) | ||||
Antivirus treatment | 100 (100) | 51 (100) | 49 (100) | |
median (IQR), days | ||||
Time from illness onset to Antivirus start | 7 (4–9.5) | 6 (3–9) | 7 (5–10) | 0.2948 |
Glucocorticoid treatment n (%) | 81 (81) | 33 (64.7) | 48 (98) | < 0.0001 |
Maximum dosage | 80 (20–80) | 80 (0–40) | 80 (40–80) | 0.0001 |
(equivalent methylprednisolone), median (IQR), mg/d | ||||
Artificial liver support n (%) | 9 (9) | 1 (2) | 8 (16.3) | 0.0148 |
Antibiotic treatment n (%) | 24 (24) | 2 (3.9) | 22 (44.9) | < 0.0001 |
Oxygen support | < 0.0001 | |||
Nasal cannular | 64 (64) | 46 (90.2) | 18 (36.7) | |
high-flow nasal cannula | 13 (13) | 3 (5.9) | 10 (20.4) | |
Invasive mechanical ventilation | 23 (23) | 2 (3.9) | 21 (42.9) | |
median (IQR), days | ||||
ΑAT to first virologic conversion | 9 (5–14) | 6 (4–12) | 9 (7–15) | 0.0142 |
AT to stable virologic conversion | 10 (6–15) | 7 (4–13) | 12 (9–18) | 0.0006 |
AT to radiologic recovery | 7 (4–10) | 7 (5–11) | 6.5 (4–9.5) | 0.3162 |
AT to temperature recovery | 5 (2–8) | 3 (2–7) | 6.5 (2–9) | 0.0903 |
Clinical outcomes, n (%) | ||||
Discharge from hospital | 86 (86) | 49 (96.1) | 37 (75.5) | 0.0030 |
ΒICU admission | 23 (23) | 2 (3.9) | 21 (42.9) | < 0.0001 |
Death | 0 | 0 | 0 | 0 |